News & Events
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new...
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update.
READ MORECrinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
Crinetics company announces the appointment of Tobin Schilke as chief financial officer, effective February 28, 2025.
READ MORECrinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
Crinetics' company management will participate in the TD Cowen 45th Annual Healthcare Conference on March 3, and the Leerink Global...
READ MORECrinetics Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an...
READ MORECrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Event Date: February 27, 2025
READ MORECrinetics to Report Fourth Quarter and Full Year 2024 Financial Results
Event Date: February 27, 2025
READ MORECrinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new...
READ MORECrinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Event Date: January 10, 2025
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
